You are here: Industry Insights > Breyanzi

News List

Bristol Myers faces $6.4bn lawsuit over cancer drug delay pharmaceutical-technology
June 07, 2021
UMB Bank, a trustee for Celgene’s former shareholders, has filed a lawsuit against Bristol Myers Squibb (BMS) for allegedly delaying the development and manufacturing of cancer drug lisocabtagene maraleucel (Liso-cel) to avoid contingent value right (CVR)
BMS faces lawsuit from Celgene shareholders over missed deadline for Breyanzi approval firstwordpharma
June 04, 2021
Celgene's former shareholders sued Bristol Myers Squibb in US court on Thursday claiming that the drugmaker failed to use its best efforts to secure FDA approval of Breyanzi (lisocabtagene maraleucel) by the end of 2020
BMS to invest in new cell therapy manufacturing site in Europe pharmatimes
April 26, 2021
Bristol Myers Squibb (BMS) is planning to invest in a new cell therapy manufacturing site based in Leiden in the Netherlands.
Japan approves Bristol Myers Squibb’s B-cell lymphoma therapy pharmaceutical-business-review
March 31, 2021
Bristol Myers Squibb has received Japan’s Ministry of Health, Labour and Welfare (MHLW) approval for its Breyanzi (lisocabtagene maraleucel; liso-cel) to treat patients suffering from relapsed or refractory (R/R) large B-cell lymphoma (LBCL) and R/R ...
FDA Approves BMS CAR-T Cell Therapy contractpharma
February 10, 2021
Breyanzi is a CD19-directed chimeric antigen receptor (CAR) T cell therapy for the treatment of relapsed or refractory large B-cell lymphoma.
FDA approves third gene therapy for large B-cell lymphoma europeanpharmaceuticalreview
February 09, 2021
Breyanzi (lisocabtagene maraleucel) was approved on the 54 percent complete remission rate achieved in diffuse large B-cell lymphoma trials.